Literature DB >> 3787424

Evaluation of computed tomography guided percutaneous biopsy of the pancreas.

J E Dickey, J R Haaga, T A Stellato, C L Schultz, T Hau.   

Abstract

The results of 96 computed tomography guided percutaneous pancreatic aspiration biopsies were reviewed to evaluate the diagnostic sensitivity, specificity and accuracy in pancreatic mass lesions. These were assessed by comparing pathology results to findings at subsequent laparotomy, autopsy or to immediate and long term clinical findings. Effects of varying the size of the biopsy needle and the number of aspirations performed were examined. Of the primary tumors of the pancreas in which adequate material was obtained, 97.3 per cent were correctly diagnosed with one false-negative and no false-positive results. The over-all sensitivity rate for primary tumor so the pancreas was 71.9 per cent using a No. 22 gauge "skinny" needle and 86.7 per cent using a No. 20 gauge needle. Over-all diagnostic accuracy for all types of lesions was 61.8 per cent using a No. 22 gauge needle and 73.3 per cent using a No. 20 gauge needle. A No. 19 gauge needle with a sheath was used on lesions with fluid or necrotic debris when a pseudocyst was a possibility. Over-all diagnostic accuracy using a No. 19 gauge sheathed needle was 81.8 per cent on all types of lesions. There was no benefit in using two passes versus a single aspiration. There were no complications, regardless of the needle size or number of passes. The serum amylase level increased in one instance after biopsy and this returned to normal a few days after biopsy. Computed tomography guided aspirations are safe and effective in evaluation of focal or diffuse enlargements of the pancreas when proper techniques and appropriate precautions are used.

Entities:  

Mesh:

Year:  1986        PMID: 3787424

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  10 in total

Review 1.  Biopsy needle characteristics.

Authors:  G S Gazelle; J R Haaga
Journal:  Cardiovasc Intervent Radiol       Date:  1991 Jan-Feb       Impact factor: 2.740

Review 2.  Percutaneous biopsy of pancreatic lesions.

Authors:  J Neuerburg; R W Günther
Journal:  Cardiovasc Intervent Radiol       Date:  1991 Jan-Feb       Impact factor: 2.740

3.  Computed tomography-guided percutaneous core needle biopsy in pancreatic tumor diagnosis.

Authors:  Chiang J Tyng; Maria Fernanda A Almeida; Paula N V Barbosa; Almir G V Bitencourt; José Augusto A G Berg; Macello S Maciel; Felipe J F Coimbra; Luiz Henrique O Schiavon; Maria Dirlei Begnami; Marcos D Guimarães; Charles E Zurstrassen; Rubens Chojniak
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 4.  Pancreatic cancer in 1988. Possibilities and probabilities.

Authors:  A L Warshaw; R S Swanson
Journal:  Ann Surg       Date:  1988-11       Impact factor: 12.969

5.  Fine needle biopsy: effect of needle size.

Authors:  F Mutch
Journal:  Gut       Date:  1987-07       Impact factor: 23.059

6.  Diagnostic dilemmas in patients with cystic neoplasms of the pancreas.

Authors:  R H Turnage; F E Eckhauser; A I Vinik; W E Strodel; N W Thompson; A Smid; D Smid
Journal:  Int J Pancreatol       Date:  1988-12

7.  Pancreatic cancer cell DNA content correlates with long-term survival after pancreatoduodenectomy.

Authors:  D C Allison; K K Bose; R H Hruban; S Piantadosi; W C Dooley; J K Boitnott; J L Cameron
Journal:  Ann Surg       Date:  1991-12       Impact factor: 12.969

Review 8.  Overview of pancreatic cancer, 1989.

Authors:  I Cohn
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

9.  Role of fine needle aspiration cytology and endoscopic biopsy in the preoperative assessment of pancreatic and peripancreatic malignancies.

Authors:  R Nakamura; R Machado; K Amikura; B Ruebner; C F Frey
Journal:  Int J Pancreatol       Date:  1994-08

10.  Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancer.

Authors:  Wang Zhongmin; Liu Yu; Liu Fenju; Chen Kemin; Huang Gang
Journal:  Eur Radiol       Date:  2010-01-13       Impact factor: 5.315

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.